The tree · Energy and fuel sensing
A drug is approved to make dogs live longer
Dogs share our homes, our food and many of our diseases, and they age fast enough that a lifespan trial finishes in years, not decades. A drug approved to lengthen a dog's life would be the first approval of its kind in any species. One company, Loyal, has taken three such drugs to the United States veterinary regulator and has had the regulator accept that each can reasonably be expected to work. None has yet been approved, and none has yet been shown to lengthen dogs' lives in a published, peer-reviewed report. The leaf sits beside the human ones on this branch because it is the first place a regulator is being asked to put "extends lifespan" on a label.
What would count
A regulator (the United States Food and Drug Administration's Center for Veterinary Medicine, or the regulator of any other country) grants an approval, full or conditional, for a drug whose stated purpose is to extend the lifespan of dogs, or their healthy lifespan, in the regulator's own approval record. A conditional approval counts for the clinic rung, because under it a veterinarian can prescribe the drug outside a trial; the leaf notes whether the approval is conditional. Acceptance of one section of an application, a company's announcement and a supplement sold without approval are not the leaf. For the first rung above idea only: a peer-reviewed report that dogs given such a drug lived longer, or stayed free of age-related disease longer, than dogs given a placebo.
Who settles it: The regulator's own approval record; for the first rung, the peer-reviewed report of the trial.
Where it stands
Idea only. Not yet shown to work in any living animal, so there is no record to point at. Next rung within 1 to 5 years.
When it reaches the clinic: the project's estimate
This is the one thing on this page that is a judgment rather than a record. The project's estimate of the year it reaches the clinic is 2028, no earlier than 2027 and no later than 2032; the model draws from that range every run, with the likely year the most probable draw. Set 17 October 2026, a first pass awaiting an outside review.
| Rung | No earlier than | Most likely | No later than | |
|---|---|---|---|---|
| In clinical use | 2027 | 2028 | 2032 | feeds the year at the top |
Why. The company's own timetable is the only schedule there is, and it has slipped once: in February 2025 it expected the manufacturing and safety sections by the end of 2025; safety was accepted in January 2026 and manufacturing was still open when its next posts went out, with the application now expected in 2027. Approval then needs the regulator's review of the full application, so the likely year is 2028, a year after the application. The earliest assumes the review is quick because the regulator has already accepted two of the three sections; the latest allows for manufacturing problems, for the regulator asking for more, or for the company running short of money, which in a company with one product family is a real risk.
Changes to this record
None since it was written on 17 October 2026. Every change to the stage or the estimate lands here with its date, the old value, the new one and the reason, and a change to the estimate never happens because a number looked wrong: it needs a dated reason and a source.
The last readings
- 17 October 2026 Quiet
Nothing in the window: no approval, conditional or full, of any dog-lifespan drug was found, and no company post, regulator notice or peer-reviewed trial report dated 2026-10-10 to 2026-10-17. The newest items seen were the company's safety-section acceptance of 2026-01-13, which the record already holds, a report that the company raised a 100 million dollar funding round in February 2026 (funding, not the record), and company pages saying the manufacturing section is the one outstanding step with the application expected in 2027, as the record says. The company's newsroom and the regulator's list of conditional approvals could not be opened from this session (the network refused loyal.com and fda.gov), so the first fact on the verify list, that no regulator had approved such a drug as of 2026-10-17, stays checked by search only.source 1, source 2, source 3, source 4
What the story so far says about it
Promised, in public
- 26 February 2025Loyal: The two remaining sections of the conditional-approval application for LOY-002 complete by the end of 2025, and, in the same post, an approved longevity drug for millions of dogs within the next year.
Notes
Why the stage is idea only (ruled by John on 2026-10-17 as the verify session proposed). The ladder is written for treatments meant for people, and its second rung asks for a peer-reviewed report that the treatment works in a living animal. Loyal has given the drug to more than 400 dogs in safety work and to 48 in a three-month pilot, and the regulator has accepted that the company's data give a reasonable expectation of effectiveness (accepted 2025-02-26 for LOY-002, the senior-dog drug; the large-dog drugs LOY-001 and LOY-003 were accepted earlier and on 2026-09-16 respectively), and the safety section for LOY-002 was accepted on 2026-01-13. But the effectiveness evidence behind those acceptances is the company's own, not a peer-reviewed report of dogs living longer, and the pivotal trial (STAY: first dog dosed in December 2023, about 1,000 to 1,300 dogs at 55 to 70 clinics, about four years) has not read out. Read strictly, the record supports idea only. The alternative is shown in animals, on the regulator's acceptance of effectiveness; that would credit a private data package that no reader can check, so it was not taken. What counts as the clinic. Under the regulator's expanded conditional approval route a drug may be conditionally approved on full safety data, full manufacturing data and a reasonable expectation of effectiveness, for up to five years while the full trial finishes, and a veterinarian may prescribe it as normal in that time. This leaf counts such an approval as the clinic rung, which is a lower bar than the human leaves on this branch clear; a stricter test would wait for the full approval, perhaps two years later than the estimate. It is a judgment call, and John ruled on 2026-10-17 that the conditional approval counts as the clinic rung. What this does to the headline. The leaf is on the energy and fuel branch because the drug (LOY-002) is said to act on the metabolic dysfunction of ageing, and because the claims log already files the Loyal claim there. Its early clinic estimate would make it the second leaf of that branch to reach the clinic, so the branch would count as handled much earlier than before. Run `scripts/compute.py run` to see the effect; the verify session's report to John gives the numbers before and after. An approval for dogs says nothing yet about people, which is the other reason this leaf was put to John; he ruled on 2026-10-17 that the leaf stands with the stage idea only and the estimate as proposed (earliest 2027, likely 2028, latest 2032). Related: loyal-2025-senior-dog-approval-by-end-of-2025 (the end-of-2025 promise, missed).
Not yet verified
These facts in the record were written from memory or from a secondary source and have not yet been checked against the paper, the regulator's record or the registry. Nothing here is presented as settled until it is cleared, by checking it and either deleting the line or correcting the record.
- That no lifespan drug for dogs had been approved by any regulator as of 2026-10-17 rests on the company's own posts and a web search; the regulator's own list of conditional approvals was not read.
- That the manufacturing section of the application was still outstanding on 2026-10-17, with the application now expected in 2027, is from the company's post of 2026-01-13 as the claims log records it and from the company's for-vets page, which lists the manufacturing section as in progress; a later company or regulator statement may exist.